MDS Pharma Services write-down pegged at US$320 million
Canadian life sciences company MDS has set at US$320 million the final value of a goodwill write-down for its troubled contract research division MDS Pharma Services.
Read MoreAuthor: Peter Mansell
Kendle tightens guidance for 2008
Kendle has joined the ranks of US-based contract research organisations (CROs) moderating their financial guidance for 2008 in the face of a contracting global economy.
Read MoreAntipsychotic mortality study another blow to the ‘chemical cosh’
Efforts to curb the routine use of antipsychotics as a behavioural management tool in the elderly have been further bolstered by the publication of study results suggesting that antipsychotic treatment of people with dementia nearly doubled the risk of death over a three-year period.
Read MoreFrance losing traction as European trial site
France is holding its own internationally as a location for later-phase clinical trials. Within Europe, though, the country has been losing ground, essentially to the benefit of the UK and the countries of Eastern Europe, according to the latest biennial analysis by the French pharmaceutical industry association Leem (Les enterprises du medicament).
Read MoreFDA falling down on investigator financial interest checks
The US Food and Drug Administration needs to step up its efforts to ensure that clinical trial sponsors are properly disclosing investigators’ financial interests and minimise any potential conflicts of interest, says a report from the Department of Health and Human Services’ Office of Inspector General (OIG).
Read More- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
